Mitsui Chemicals JSR Acquisition $11.6 Billion Explained: Photoresists, the ¥1.84 Trillion Deal and What It Means for India
Photoresist — the light-sensitive material at the heart of the Mitsui–JSR deal — seen under a scanning electron microscope. Image: Wikimedia Commons / EdC, CC BY-SA 3.0
TL;DR: The Mitsui Chemicals JSR acquisition, worth $11.6 billion, was signed on 9 November 2026: Mitsui and Japan's Development Bank will buy photoresist maker JSR from state-backed fund JIC for ¥1.84 trillion. JSR's light-sensitive coatings are essential to making every advanced chip, and Mitsui is borrowing heavily to own them — its shares fell about 9% on the news, and the deal will not close before late 2027 at the earliest.
📌 KEY HIGHLIGHTS
- Mitsui Chemicals' board approved the deal on 9 November 2026 and signed a share purchase agreement with funds managed by JIC Capital to acquire all of JSR's common shares for ¥1.84 trillion ($11.61 billion).
- The price breaks down into ¥1,392.1 billion of equity value — including a ¥200 billion investment from the Development Bank of Japan — plus ¥447.9 billion of interest-bearing debt and other items.
- JSR makes photoresists, the light-sensitive coatings that print circuit patterns onto silicon wafers. Nikkei reports it is the world's second-largest photoresist maker, behind Tokyo Ohka Kogyo.
- Mitsui will fund the deal with a ¥1.64 trillion bridge loan and expects its Net Debt/EBITDA to temporarily exceed four times after completion — a debt load the market immediately questioned.
- Completion needs competition and foreign-investment approvals in Japan and overseas. Mitsui is targeting the second half of the fiscal year ending March 2028.
What happened?
On Monday 9 November 2026, Mitsui Chemicals announced that its board had approved the acquisition of JSR Corporation and signed a share purchase agreement with investment funds managed by JIC Capital, the private-equity arm of Japan Investment Corp (JIC), a state-backed fund. The Development Bank of Japan (DBJ) is co-investing ¥200 billion and will end up holding non-voting preferred shares, while Mitsui will hold 100% of the voting rights.
The sellers are two JIC funds that own almost all of JSR — JIC PEFJ1 holds 89.72% of the shares and JIC PEF1 holds 6.75%. Mitsui is acquiring 102,242,573 common shares, plus Class A and Class B preferred shares held by Mizuho Bank and DBJ, which will convert into common shares after the deal closes. JSR and four of its affiliates — including Inpria, a US developer of EUV resists, and KBI Biopharma, a contract drug manufacturer — will become Mitsui subsidiaries.
| Deal term | Detail |
|---|---|
| Buyer | Mitsui Chemicals, with the Development Bank of Japan (DBJ) |
| Seller | Funds managed by JIC Capital (Japan Investment Corp) |
| Total price | ¥1.84 trillion ($11.61 billion at ¥158.45 to the dollar) |
| Equity value | ¥1,392.1 billion, including DBJ's ¥200 billion investment |
| Debt and other items | ¥447.9 billion |
| Financing | ¥1.64 trillion bridge loan + DBJ's ¥200 billion investment |
| Refinancing plan | Bank loans, bonds, up to ¥150 billion of new shares, mezzanine financing |
| Announced / signed | 9 November 2026 |
| Target completion | Second half of the fiscal year ending March 2028 |
The deal is the largest yet in Japan's chemicals sector, according to Reuters, and it closes a sale process that has been running since spring — JIC Capital's president, Shogo Ikeuchi, said seven or eight potential buyers were considered. Reuters first reported on 4 November that Mitsui was the preferred bidder; Mitsui said at the time that nothing had been decided. Five days later, the agreement was signed.
Mitsui Chemicals JSR acquisition 11.6 billion explained: what JSR actually makes
JSR's core product is the photoresist. It is a light-sensitive coating spread over a silicon wafer; during lithography, light shines through a patterned mask and the resist records the circuit design, which is then etched into the chip. Without photoresist, no modern processor, memory chip or AI accelerator can be printed. The most advanced version — EUV (extreme ultraviolet) resist — is needed for the smallest, most powerful chips, and only a handful of companies in the world can make it.
That scarcity is exactly what Mitsui is buying. JSR also owns Inpria, a US company in Corvallis, Oregon, that develops metal-oxide resists for EUV lithography — a bet on the next generation of chipmaking, although Inpria is still loss-making. Beyond semiconductors, JSR makes display materials, and its life-sciences arm (contract drug manufacturing through KBI Biopharma) is treated as non-core: Mitsui says JSR will keep exploring all options for it, including a sale.
JSR's own numbers explain why JIC is selling now. The company swung from a ¥217.51 billion attributable loss in the fiscal year ended March 2025 to a ¥59.33 billion profit in the year ended March 2026, while revenue rose to ¥440.72 billion. JIC took JSR private in 2024 for about ¥900 billion (roughly $6 billion) and delisted it; at an equity value of ¥1,392.1 billion, the state-backed fund is exiting with a large gain after about two years of restructuring.
| JSR financials (¥ billion) | Year ended Mar 2025 | Year ended Mar 2026 |
|---|---|---|
| Revenue | 388.77 | 440.72 |
| Core operating profit | -1.61 | 62.35 |
| Operating profit | -204.43 | 40.53 |
| Profit (loss) attributable to owners | -217.51 | 59.33 |
| Total assets | 1,142.06 | 1,171.09 |
Source: Mitsui Chemicals' official disclosure, 9 November 2026. JSR employs 6,951 people on a consolidated basis.
A silicon wafer of the kind photoresists help pattern into chips. Image: Wikimedia Commons / Sangitiana Fararano, CC BY-SA 2.0
Why Mitsui is paying $11.6 billion
Mitsui's reasoning is strategic, not opportunistic. Under its long-term plan "VISION 2030", the company is shifting away from low-margin petrochemicals toward high-value specialty chemicals, and it calls JSR the future core of its ICT Solutions business. The plan is to combine JSR's advanced photoresists with Mitsui's own semiconductor products — MITSUI PELLICLE films that protect photomasks in front-end chipmaking, and ICROS Tape and thick-film resists used in chip packaging — to create one of Japan's largest semiconductor materials makers by sales.
Mitsui expects the combination to add about ¥40 billion a year in incremental profit by fiscal 2035 through growth and cost synergies. That is the company's own target, not a guaranteed outcome, and it is a long way off: the deal will not even close for well over a year. Mitsui also expects to unlock more than ¥350 billion of business value from capital-efficiency measures, including selling non-core assets and shareholdings.
The price itself is rich. At ¥1.84 trillion, Mitsui is paying about 29.5 times JSR's latest core operating profit, and the deal is worth roughly 2.3 times Mitsui Chemicals' own market capitalisation — which is why the market reacted badly. Mitsui's chief executive, Satoshi Ichimura, told a press conference that buying JSR is "not simply about strengthening our semiconductor materials business, but a strategic deal to accelerate the transformation of our portfolio." Investors, for now, are focused on the bill: Mitsui shares fell about 9% on Monday, extending a slide that began when Reuters first named it as the buyer last week.
There is also a national-policy backdrop. Japan's government has been pushing to consolidate its semiconductor materials industry and strengthen its competitiveness against rivals in Taiwan, South Korea and China. JIC — overseen by Japan's finance ministry — bought JSR precisely to drive that consolidation, and selling it to Mitsui, with DBJ co-investing, is the next step in the same plan rather than a simple exit.
What it means for India
There are no direct India terms in this deal — no Indian factory, no Indian buyer, no rupee figure. Its relevance to India is indirect but real, because photoresist is a chokepoint input: every chip fab in the world buys it from a tiny group of Japanese suppliers, and this deal concentrates that group further.
India is courting chipmakers to build fabs at home, and every one of those fabs would buy photoresists from suppliers like the combined Mitsui–JSR. A larger, better-funded Japanese supplier could mean more stable supply and more R&D investment in advanced resists — good news for any fab. The risk runs the other way: greater concentration can also mean less competition on price and fewer alternative suppliers if supply is disrupted. For Indian readers, the practical takeaway is that the materials layer of the chip supply chain — the part India does not yet make at home — is consolidating in Japan, and India's fab plans depend on it staying open and competitive.
The deal also fits a pattern worth watching. Like IonQ's $1.15 billion all-stock acquisition of Elisity, which closed this month, and AdaniConneX's ₹1,085.51 crore Vizag data centre acquisition, it shows big buyers paying up for scarce, strategic assets — in this case, the chemistry that makes advanced chips possible. Docusign's acquisition of Suplari is another recent example of the same consolidation wave in a different sector.
Should you care?
✅ Verdict: worth following, not worth acting on yet. If you follow chips, semiconductors or India's fab ambitions, this deal reshapes one of the industry's most concentrated supply chains — but it is signed, not closed, and the payoff Mitsui promises is dated 2035. The honest risks are all in Mitsui's own filing: a ¥1.64 trillion bridge loan, Net Debt/EBITDA set to exceed four times, and regulatory approvals still to come. Watch the approvals, not the announcement.
What happens next
The deal now goes to regulators. It needs competition-law and foreign-investment approvals in Japan and other jurisdictions, and Mitsui says it is difficult to predict how long those procedures will take — hence the target of the second half of the fiscal year ending March 2028, with a warning that the date may change. The final price is also subject to adjustments at closing.
On financing, the first milestone is near: Mitsui's shelf registration for up to ¥150 billion of new shares takes effect on 17 November 2026 and runs for two years. Within a year of completion, Mitsui aims to raise funds equivalent to ¥300 billion that rating agencies will recognise as equity, to restore its financial soundness and keep its credit rating in the "A" category. It has capped the new-share portion at ¥150 billion to limit dilution for existing shareholders, with mezzanine financing covering the rest.
Other things to watch: whether JSR's life-sciences business is sold, whether the promised synergies survive contact with two large organisations, and whether Mitsui's shares recover once the market prices in the debt. If approvals land on schedule, Japan will have a new semiconductor-materials giant — and every chipmaker, including any future Indian fab, will be buying from it.
FAQs
What is JSR?
JSR Corporation is a Tokyo-based maker of advanced semiconductor and display materials, best known for photoresists — the light-sensitive coatings used to print circuits onto silicon wafers. It reported revenue of ¥440.72 billion and a profit of ¥59.33 billion for the year ended March 2026, employs 6,951 people, and also owns Inpria, a US developer of EUV resists, and the contract drug manufacturer KBI Biopharma.
Why is Mitsui Chemicals buying JSR?
Mitsui wants JSR to become the core of its ICT Solutions business under its VISION 2030 plan, which shifts the company from low-margin petrochemicals toward high-value specialty chemicals. Combining JSR's photoresists with Mitsui's pellicles, tapes and packaging resists would create one of Japan's largest semiconductor materials makers by sales, with a targeted ¥40 billion a year of extra profit from synergies by fiscal 2035.
What is a photoresist and why does it matter?
A photoresist is a light-sensitive coating spread on a silicon wafer. During lithography, light shines through a patterned mask and the resist records the circuit design, which is then etched into the chip. No modern processor, memory chip or AI accelerator can be made without it, and only a handful of companies — led by Japan's JSR and Tokyo Ohka Kogyo — can make the most advanced versions.
When will the Mitsui–JSR deal close?
Not soon. The deal needs competition and foreign-investment approvals in Japan and overseas, and Mitsui is targeting completion in the second half of the fiscal year ending March 2028 — so late 2027 at the earliest. The company says the schedule may change depending on how long the regulatory procedures take, and the final price is subject to adjustments at closing.
Takeaway
Mitsui Chemicals is paying $11.6 billion — about 2.3 times its own market value — to own the chemistry behind every advanced chip. JSR's photoresists are genuinely scarce and strategically vital, which justifies the ambition; the debt, the distant 2028 closing and the 2035 synergy target justify the market's scepticism. If you track India's chip plans, keep an eye on the regulatory filings — approval in Japan and overseas is the next milestone before this deal can close.
Sources
- Mitsui Chemicals — Notice Regarding Execution of a Share Purchase Agreement for Shares of JSR Corporation (official disclosure, 9 November 2026)
- Reuters — Mitsui Chemicals and DBJ to buy JSR for $11.6 billion, filing shows (9 November 2026)
- TechNode Global — Mitsui Chemicals to acquire JSR for 1.84T yen (9 November 2026)
- XenoSpectrum — Mitsui Chemicals to Buy JSR for ¥1.84 Trillion, About 2.3 Times Its Own Market Cap (9 November 2026)
- Maeil Business Newspaper — Mitsui Chemicals moves to acquire JSR (5 November 2026)
Comments
Post a Comment